Life Sciences In Vitro Diagnostics Solutions sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences In Vitro Diagnostics Solutions
1.1 - About Life Sciences In Vitro Diagnostics Solutions sector
Companies in Life Sciences In Vitro Diagnostics Solutions provide clinical testing products and lab services that detect, stratify, and monitor disease using molecular, genomic, and immunoassay technologies. They develop and run NGS-based tumor profiling, gene expression assays, blood-based risk tests, metabolomics panels, and rapid point-of-care kits, supported by ISO13485 manufacturing and regulated lab operations, enabling precise diagnoses, therapy selection, and scalable screening across oncology and other indications.
These companies deliver whole‑exome and transcriptome sequencing with matched tumor‑normal analysis to identify actionable variants. They develop gene expression classifiers for prognosis, run qPCR and ddPCR workflows, and perform flow cytometry integrated with spatial tissue analysis. Offerings typically extend to FISH and cytogenetics plus comprehensive pathology and histology, along with metabolomics and lipidomics profiling. Many add cell therapy testing, clinical trial matching, and ISO13485 lateral‑flow development-to-scale manufacturing that bridges assay design, tech transfer, and compliant high‑volume production.
Primary customers include hospital and reference laboratories, oncology practices, and biopharma development teams. Outcomes typically include earlier and more accurate diagnosis, risk stratification and therapy selection, faster turnaround times for clinical decisions, improved trial enrollment and biomarker qualification, and the ability to scale point‑of‑care screening through compliant manufacturing and supply chains, reducing operational risk while expanding access to testing across diverse patient populations.
2. Buyers in the Life Sciences In Vitro Diagnostics Solutions sector
2.1 Top strategic acquirers of Life Sciences In Vitro Diagnostics Solutions companies
Exact Sciences
- Description: Provider of full-spectrum cancer diagnostic solutions offering early detection, treatment guidance, monitoring and therapy-selection tests, including multi-cancer blood screening, noninvasive colorectal stool testing, tumor-informed profiling and hereditary risk assessment for patients and health systems.
- Key Products:
- OncoExTra™ therapy selection test: Comprehensive DNA and RNA next-generation sequencing profiles whole exome and transcriptome (~20,000 genes) with matched tumor-normal analysis, reporting targetable mutations, fusions
- IO signatures and clinical trials to guide treatment for advanced solid tumors
- Oncotype DX Breast Recurrence Score® test: Genomic assay that predicts chemotherapy benefit and risk of recurrence in invasive breast cancer, recognized as standard of care and embedded in major treatment guidelines
- Cologuard Plus™ test: Non-invasive colorectal cancer screening assay positioned to transform colorectal cancer detection and screening for patients
- Oncodetect™ molecular residual disease test: Blood-based MRD assay for colorectal cancer with Medicare coverage, enabling detection of minimal residual disease and informing post-treatment management.
- Rationale: Provider of OncoExTra therapy-selection NGS profiling, Oncotype DX Breast Recurrence Score genomic assay, and Cologuard Plus colorectal cancer screening test.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences In Vitro Diagnostics Solutions sector
M&A buyer group 1: Point of Care Diagnostics
LumiraDx
- Type: N/A
- Employees: ●●●●●
- Description: Provider of a next-generation, point-of-care diagnostic platform that integrates a small portable instrument, microfluidic test strips, and secure cloud connectivity to deliver laboratory-comparable results within minutes wherever the patient is located.
- Key Products:
- LumiraDx Instrument: Portable 1.1 kg analyzer powered by battery or mains, controlling optics, temperature and other parameters to run assays and deliver lab-quality results in minutes
- LumiraDx Microfluidic Test Strip: Single-use strip with RFID lot calibration enabling enzyme and immunoassay testing while monitoring positioning, haematocrit, expiry and other variables for precise measurements
- LumiraDx Digital Connectivity: Secure cloud and hospital IT integration that transfers calibration files instantly, supports seamless data flow and enables standardized workflows at point of care
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences In Vitro Diagnostics Solutions sector
3.1 - Buyout funds in the Life Sciences In Vitro Diagnostics Solutions sector
2.2 - Strategic buyer groups for Life Sciences In Vitro Diagnostics Solutions sector
4 - Top valuation comps for Life Sciences In Vitro Diagnostics Solutions companies
4.2 - Public trading comparable groups for Life Sciences In Vitro Diagnostics Solutions sector
Valuation benchmark group 1: Molecular Diagnostics and Genomics Tools Companies
Agilent Technologies
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of design, manufacturing, and marketing of measurement instruments primarily for communications, electronics, life sciences, and chemistry sectors.
- Key Products:
- Gas Chromatographs: Instruments for separating chemical compounds into individual components for analysis
- Liquid Chromatographs: Tools for separating, identifying, and quantifying components in a liquid sample
- Mass Spectrometers: Analyzers for identifying chemical structures and determining molecule weights
- Lab Automation Systems: Robots and software for enhancing efficiency in laboratory workflows
- Genomics Solutions: Products for gene sequencing, expression analysis, and mutation detection.